Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2026)

Takeda Pharmaceutical's Non-Current Debt history runs 9 years deep, the most recent figure standing at $27.9 billion for Q1 2026.

• In Q1 2026, Non-Current Debt rose 7.18% year-over-year to $27.9 billion; the TTM figure through Mar 2026 stood at $27.9 billion (up 7.18% YoY), while the FY2026 annual figure was $29.0 billion, up 11.48% from the prior year.
• Non-Current Debt was $27.9 billion for Q1 2026 at Takeda Pharmaceutical, roughly flat from $27.7 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $33.4 billion in Q2 2022 to a low of $4.0 billion in Q1 2022.
• Historically, Non-Current Debt has averaged $26.7 billion across 5 years, with a median of $29.5 billion in 2025.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt surged 657.41% in 2023, then plunged 84.81% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $27.7 billion in 2022, then grew by 4.83% to $29.0 billion in 2023, then rose by 6.53% to $30.9 billion in 2024, then slipped by 10.34% to $27.7 billion in 2025, then gained by 0.42% to $27.9 billion in 2026.
• The last three Non-Current Debt figures came in at $27.9 billion (Q1 2026), $27.7 billion (Q4 2025), and $29.5 billion (Q3 2025), per Business Quant data.